Strategic partnerships Leverage the recent BioSymetrics collaboration to position Moleculera as a partner for AI-driven patient analytics and drug discovery, highlighting access to a large clinically annotated biorepository and immune-mediated specimen datasets to accelerate diagnostic and therapeutic development.

Clinical expansion Promote the Autoimmune Brain Panel as a scalable diagnostic service for autoimmune-based neuropsychiatric disorders, emphasizing its role in guiding treatable autoimmune etiologies behind OCD, tics, anxiety, ADHD, and autism-related behaviors to expand lab testing volume.

Advisory and funding signals Leverage recent board advisory appointments and strategic finance expertise to approach biotech investors and payers with a roadmap for enhanced clinical utility, reimbursement potential, and governance improvements that can support larger-scale deployments.

Clinical lab capabilities Highlight the CLIA/COLA-accredited, specialized molecular diagnostics capability to attract pharma and contract research organizations seeking precise immune-mediated assay services for patient stratification, trial enrollment, and biomarker-driven development.

Strategic partnerships Identify opportunities to partner with genomics and AI analytics players (e.g., General Genomics) to co-develop predictive treatment algorithms, enabling joint offerings that combine genomic, immunologic, and neuropsychiatric insights for value-based care.